CALC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
CalciMedica Inc (CALC) is not a good buy for a beginner, long-term investor at this time. The stock is currently in a bearish technical trend, lacks positive news catalysts, and has been downgraded by analysts due to the discontinuation of a key clinical trial. Additionally, the financial performance shows no revenue growth and significant losses. While there is some potential in the company's pipeline, it is not enough to justify investment given the current uncertainties.
The stock is in a bearish trend with the MACD histogram below 0 (-0.123) and negatively contracting, RSI indicating oversold conditions at 16.066, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot point of 0.741, with key support at 0.55 and resistance at 0.932.
NULL currently. Oppenheimer sees the stock as oversold and undervalued, citing potential in Auxora's $200M opportunity in AP, but this is speculative and contingent on future developments.
Discontinuation of the Phase 2 KOURAGE clinical trial due to safety concerns has removed a major catalyst for the stock. Analysts have downgraded the stock, and there is no recent positive news or significant insider/hedge fund activity.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$7.8M (improved 38.91% YoY), and an EPS of -0.52 (up 4.00% YoY). Gross margin remains at 0%. Overall, the financials show no growth and continued losses.
Analysts have downgraded the stock. H.C. Wainwright moved the rating to Neutral from Buy, citing the discontinuation of the Phase 2 KOURAGE trial. Oppenheimer sees the stock as oversold but acknowledges significant uncertainty due to the trial's discontinuation.
